MESA-LVH

1. MESA-LVH predicts heart failure hospitalization in humans (HR 2.73, 95% CI 1.34–5.56).

   “heart-failure hospitalization (HR 4.21 at ≥60 mm), which remained associated after adjustment for continuous LV mass index (HR 2.73, 95% CI 1.34-5.56).”

   HumansMESA-LVH ≥60 mm; adjusted for continuous LV mass indexn = 4,644

   Graded MESA-LVH as a marker of left ventricular electrical remodeling: spectrum-based diagnosis, prognosis analysis

   Journal of electrocardiology·2 Oct 2026

1. MESA-LVH predicts death-or-MACE in humans (HR 1.61).

   “≥60 mm predicted MACE (HR 2.08) and, less robustly, death-or-MACE (HR 1.61).”

   HumansMESA-LVH ≥60 mm; adjusted for clinical covariates and CMR-LVHn = 4,644

   Graded MESA-LVH as a marker of left ventricular electrical remodeling: spectrum-based diagnosis, prognosis analysis

   Journal of electrocardiology·2 Oct 2026

1. MESA-LVH predicts major adverse cardiovascular events in humans (HR 2.08 at ≥60 mm; HR 1.41 at ≥50 mm).

   “After CMR-LVH adjustment, MESA-LVH ≥50 mm predicted MACE (HR 1.41), and ≥60 mm predicted MACE (HR 2.08)”

   HumansMESA-LVH ≥60 mm; adjusted for clinical covariates and CMR-LVHn = 4,644

   Graded MESA-LVH as a marker of left ventricular electrical remodeling: spectrum-based diagnosis, prognosis analysis

   Journal of electrocardiology·2 Oct 2026

1. MESA-LVH is associated with CMR-defined left ventricular hypertrophy in humans (LR− ≈0.6 at <30 mm; LR+ ≈3, 5, 10 at ≥40, ≥50, ≥60 mm).

   “with LR- ≈ 0.6 at <30 mm and LR+ ≈ 3, 5, 10 at ≥40, ≥50, ≥60 mm, respectively.”

   HumansLikelihood ratios calculated at matched specificitiesheartn = 4,644

   Graded MESA-LVH as a marker of left ventricular electrical remodeling: spectrum-based diagnosis, prognosis analysis

   Journal of electrocardiology·2 Oct 2026

More on CMR-defined left ventricular hypertrophy